trial · primary record
Serplulimab
Esophageal Squamous Cell Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 90 |
| Primary completion | 2027-12-31 |
| Primary endpoint | Pathological Complete Response (pCR) Rate |
| Registry ID | NCT06601309 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:05.544Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06601309
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.